Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Gains from Sales and Divestitures (2021 - 2024)

Aligos Therapeutics (ALGS) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $4874.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Gains from Sales and Divestitures changed N/A year-over-year to $4874.0, compared with a TTM value of $4874.0 through Sep 2024, changed N/A, and an annual FY2022 reading of $89054.0, down 72.11% over the prior year.
  • Gains from Sales and Divestitures was $4874.0 for Q3 2024 at Aligos Therapeutics, up from $2490.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $319357.0 in Q4 2021 and bottomed at $2490.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 3 years is $109125.2, with a median of $89054.0 recorded in 2022.
  • Peak annual rise in Gains from Sales and Divestitures hit 35.23% in 2022, while the deepest fall reached 72.11% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $319357.0 in 2021, then plummeted by 72.11% to $89054.0 in 2022, then crashed by 94.53% to $4874.0 in 2024.
  • Business Quant data shows Gains from Sales and Divestitures for ALGS at $4874.0 in Q3 2024, $2490.0 in Q2 2024, and $2490.0 in Q1 2024.